Literature DB >> 24914138

Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.

Natasha Kekre1, Joseph H Antin1.   

Abstract

Most patients who require allogeneic stem cell transplantation do not have a matched sibling donor, and many patients do not have a matched unrelated donor. In an effort to increase the applicability of transplantation, alternative donors such as mismatched adult unrelated donors, haploidentical related donors, and umbilical cord blood stem cell products are frequently used when a well matched donor is unavailable. We do not yet have the benefit of randomized trials comparing alternative donor stem cell sources to inform the choice of donor; however, the existing data allow some inferences to be made on the basis of existing observational and phase 2 studies. All 3 alternative donor sources can provide effective lymphohematopoietic reconstitution, but time to engraftment, graft failure rate, graft-versus-host disease, transplant-related mortality, and relapse risk vary by donor source. These factors all contribute to survival outcomes and an understanding of them should help guide clinicians when choosing among alternative donor sources when a matched related or matched unrelated donor is not available.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 24914138     DOI: 10.1182/blood-2014-02-514760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  HLA testing in the molecular diagnostic laboratory.

Authors:  Kathleen Madden; Devon Chabot-Richards
Journal:  Virchows Arch       Date:  2018-12-04       Impact factor: 4.064

2.  Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.

Authors:  Masamitsu Yanada; Akiyoshi Takami; Shohei Mizuno; Jinichi Mori; Takaaki Chou; Kensuke Usuki; Hitoji Uchiyama; Itsuto Amano; Shiro Fujii; Toshihiro Miyamoto; Takeshi Saito; Tomohiko Kamimura; Tatsuo Ichinohe; Takahiro Fukuda; Shinichiro Okamoto; Yoshiko Atsuta; Shingo Yano
Journal:  Int J Hematol       Date:  2019-10-14       Impact factor: 2.490

3.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

Review 4.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

5.  Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

Authors:  A Hamblin; D M Greenfield; M Gilleece; N Salooja; M Kenyon; E Morris; N Glover; P Miller; H Braund; A Peniket; B E Shaw; J A Snowden
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

6.  The number of CD34+CD133+ hematopoietic stem cells residing in umbilical cord blood (UCB) units is not correlated with the numbers of total nucleated cells and CD34+ cells: a possible new indicator for quality evaluation of UCB units.

Authors:  Yoshikazu Matsuoka; Fumiaki Nakamura; Kazuo Hatanaka; Tatsuya Fujioka; Satoshi Otani; Takafumi Kimura; Yoshihiro Fujimura; Hiroaki Asano; Yoshiaki Sonoda
Journal:  Int J Hematol       Date:  2018-07-25       Impact factor: 2.490

7.  Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation.

Authors:  A Desjonqueres; M Illiaquer; A Duquesne; Y Le Bris; P Peterlin; T Guillaume; J Delaunay; F Rialland; P Moreau; M C Béné; P Chevallier; M Eveillard
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

8.  Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.

Authors:  Yasuhiko Shibasaki; Tatsuya Suwabe; Takayuki Katagiri; Tomoyuki Tanaka; Takashi Ushiki; Kyoko Fuse; Naoko Sato; Toshio Yano; Takashi Kuroha; Shigeo Hashimoto; Miwako Narita; Tatsuo Furukawa; Hirohito Sone; Masayoshi Masuko
Journal:  Int J Hematol       Date:  2018-05-09       Impact factor: 2.490

Review 9.  Update of hematopoietic cell transplantation for sickle cell disease.

Authors:  Mark C Walters
Journal:  Curr Opin Hematol       Date:  2015-05       Impact factor: 3.284

Review 10.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.